Modified adeno-associated virus vectors and delivery thereof into the central nervous system

Patent Citations (39)

Non-Patent Literature (60)

• Tardieu M, Zérah M, Heard JM, Danos O. Intracerebral administration of adeno-associated viral vector serotype rh. 10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. Jun. 2014;25(6):506-16. (Year: 2014).Examiner
• Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. Oct. 2015;82:495-503. (Year: 2015).Examiner
• Albright, B. H. et al., Mapping the structural determinants required for AAVrh.10 Transport across the BBB, Mol. Ther., 26(2):510-523 (2018).Applicant
• Asano, S. et al., Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc, ACS Med. Chem. Lett., 5:133-137 (2014).Applicant
• Aschauer, D. F. et al., Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain, PLoS One. 8(9):e76310 (2013).Applicant
• Asokan, A. et al., Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle, Nat. Biotechnol., 28(1):79-82 (2010).Applicant
• Bartel, M. A. et al., Directed evolution of novel adeno-associated viruses for therapeutic gene delivery, Gene Ther., 19(6):694-700 (2012).Applicant
• Bevan, A. K. et al., Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders, Mol Ther., 19(11):1971-80 (2011).Applicant
• Boutin, S. et al., Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus AAV Types 1, 2, 5, 6, 8, and 9 in the healthy population, Implications for Gene Therapy Using AAV Vectors, Hum. Gene Ther. 21(6):704-12 (2010).Applicant
• Burger, C. et al., Recombinant AAV Viral Vectors Pseudotyped with Viral Cpasids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System, Mol. Ther., 10(2):302-317 (2004).Applicant
• Cearley, C. N. and Wolfe, J. H., Transduction Characteristics of Adeno-associated Virus Vectors Expressing Cap Serotypes 7, 8, 9, and Rh10 in the Mouse Brain, Mol. Ther., 13(3):528-37 (2006).Applicant
• Cearley, C. N. et al., Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain, Mol. Ther., 16(10):1710-8 (2008).Applicant
• Ellinwood, M. N. et al., Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler Syndromes, Mol. Ther., 19(2):251-259 (2011).Applicant
• Foust, K. D. et al., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat. Biotechnol., 27(1):59-65 (2009).Applicant
• Fu, H. et al., Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III, Perspective for AAV-Mediated Gene Therapy, Hum. Gene Ther. Clin. Dev., 28:187-96 (2017).Applicant
• Girod, A. et al., Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2, Nat. Med., 5(9):1052-1056 (1999).Applicant
• Gray, S. J. et al., Directed Evolution of a Novel Adeno-associated Virus AAV Vector That Crosses the Seizure-compromised Blood-Brain Barrier BBB, Mol. Ther., 18(3):570-8 (2010).Applicant
• Gray, S. J. et al., Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates, Gene Ther. 20(4):450-9 (2013).Applicant
• Gray, S. J. et al., Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia, A comparative Study of Adult Mice and Nonhuman Primates, Mol. Ther., 19(6):1058-69 (2011).Applicant
• Hinderer, C. et al., Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals, Hum. Gene Thera., 29(1):15-24 (2018).Applicant
• Hocquemiller, M. et al., Adeno-Associated Virus-Based Gene Therapy for CNS Diseases, Human Gene Therapy, 27(7):478-496 (2016).Applicant
• Hordeaux, J. et al., The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice, Mol. Ther., 26(3):664-668 (2018).Applicant
• Hudry, E. et al., Exosome-associated AAV vector as a robust and convenient neuroscience tool, Gene Ther., 23:380-92 (2016).Applicant
• International Search Report for PCT/EP2020/081396, 5 pages (mailed Feb. 1, 2021).Applicant
• International Search Report for PCT/EP2021/080832, 9 pages (mailed Feb. 21, 2022).Applicant
• Katrekar, D. et al., Oligonucleotide conjugated multifunctional adeno-associated viruses, Sci. Rep., 8(3589):1-8 (2018).Applicant
• Koerber, J. T. et al., Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles, Nat. Protoc., 1(2):701-6 (2006).Applicant
• Kwon, I. and Schaffer, D., Designer Gene Delivery Vectors, Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer, Pharm. Res., 25(3):489-99 (2008).Applicant
• Kye-Il, J. et al., Enhanced Real-Time Monitoring of Adena-Associated Virus Trafficking by Virus-Quantum Dot Conjugates, ACS NANO, 5(5):3523-3535 (2011).Applicant
• Lee, G. K. et al., PEG Conjugation Moderately Protects Adeno-Associated Viral Vectors Against Antibody Neutralization, Biotechnol. Bioeng., 92:24-34 (2005).Applicant
• Liguore, W. A. et al., AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice, Mol. Thera., 27(11):2018-2037 (2019).Applicant
• Lykken, E. A. et al., Recent progress and considerations for AAV gene therapies targeting the central nervous system, J. Neurodev. Disord., 10(1):16 (2018).Applicant
• Maguire, C. A. et al., Microvesicle-associated AAV Vector as a Novel Gene Delivery System, Mol. Ther., 20:960-71 (2012).Applicant
• Maheshri, N. et al., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors, Nat. Biotechnol., 24(2):198-204 (2006).Applicant
• Marsic, D. and Zolotukhin, S., Altering Tropism of rAAV by Directed Evolution, Methods Mole. Biol., 1382:151-173 (2016).Applicant
• Mccurdy, V. J. et al., Sustained normalization of neurological disease after intracranial gene therapy in a feline model, Sci. Transl. Med., 6(231):1-24 (2014).Applicant
• Mcphee, S. W. J. et al., Immune responses to AAV in a phase I study for Canavan disease, J. Gene Med., 8:577-588 (2006).Applicant
• Mével, M. et al., Chemical modification of the adeno-associated virus capsid to improve gene delivery, Chem. Sci., 11:1122-1131 (2020).Applicant
• Mevel, M. et al., Chemical modificatoin of the adeno-associated virus capsid to improve gene delivery, Chem. Sci., 10 pages (2019).Applicant
• Miyake, N. et al., Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors, Brain Res., 1389:19-26 (2011).Applicant
• Niethammer, M. et al., Long-term follow-up of randomized AAV2-GAD gene therapy trial for Parkinson's diease, JCI Insight, 2(7):e90133 (2017).Applicant
• Perabo, L. et al., Artificial Evolution with Adeno-Associated Viral Libraries, Comb. Chem. High Throu. Screen., 11:118-126 (2008).Applicant
• Rabinowitz, J. E. et al., Insertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus, Virology, 265(2):274-85 (1999).Applicant
• Raja, K. S. et al., Icosahedral Virus Particles as Polyvalent Carbohydrate Display Platforms, ChemBioChem, 4:1348-1351 (2003).Applicant
• Samaranch, L. et al., AAV9-mediated Expression of a Non-self Protein in Nonhuman Primate CNS Triggers Widespread Neuroinflammation Driven by Antigen-presenting Cell Transduction, Mol. Ther., 22(2):329-37 (2014).Applicant
• Samaranch, L. et al., Adeno-Associated Virus Serotype 9 Transduction in the CNS of Nonhuman Primates, Hum. Gene Ther., 23(4):382-9 (2012).Applicant
• Sato, S. et al., Chemically Programmed Antibodies As HIV-1 Attachment Inhibitors, ACS Med. Chem. Lett., 4:460-465 (2013).Applicant
• Schaffer, D. V. and Maheshri, N., Directed Evolution of AAV Mutants for Enhanced Gene Delivery, 26th Annual International Conference of the IEEE EMBS, San Francisco, CA, 3520-3523 (Sep. 2004).Applicant
• Shen, S. et al., Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency, J. Biol. Chem., 288(40):28814-23 (2013).Applicant
• Sletten, E. M. and Bertozzi, C. R., Bioorthogonal chemistry: fishing for selectivity in a sea of functionality, Angew. Chem. Int. Ed. Engl., 48(38):6974-98 (2009).Applicant
• Taymans, J-M. et al., Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain, Hum. Gene Ther., 18(3):195-206 (2007).Applicant
• Tse, L. V. et al., Structure-guided evolution of antigenically distinct AAV variants for immune evasion, Proc. Natl. Acad. Sci. USA, 114(24):E4812-E4821 (2017).Applicant
• Vite, C. H. et al., Effective Gene Therapy for an Inherited CNS Disease in a Large Animal Model, Ann. Neurol., 57:355-364 (2005).Applicant
• Vite, C. H. et al., Effective Gene Therapy for an Inherited CNS Disease in a Large Animal Model, Annals Neuro., 57(3):355-364 (2005).Applicant
• Watakabe, A. et al., Comparative analyses of AAV vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex, Neurosci. Res., 93:144-57 (2015).Applicant
• Wobus, C. E. et al., Monoclonal Antibodies against the Adena-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection, Jrnl. Viro., 74(19):9281-9293 (2000).Applicant
• Zuleta, A. et al., AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease, Biochem. Biophys. Res. Comm., 420(3):558-563 (2012).Applicant
• Beutler, A.S., AAV Provides an Alternative for Gene Therapy of the Peripheral Sensory (or Central) Nervous System, Mol Ther., 18(4): 670-673. (2010).Applicant
• Mehta, P.D. et al., 2-Azetindinone—A New Profile of Various Pharmacological Activities, Eu. J. of Med. Chem., 45(12): 551-5560 (2010).Applicant
• Nicolson, S.C. et al., Identification and Validation of Small Molecules That Enhance Recombinant Adena-associated Virus Transduction following High-Throughput Screens, J. Virology, 90(16): 7019-7031 (2016).Applicant